Wrap Text
Notification of transactions by persons discharging managerial responsibilities and persons closely associated
Mediclinic International plc
(Incorporated in England and Wales)
Company Number: 08338604
LSE Share Code: MDC
JSE Share Code: MEI
NSX Share Code: MEP
ISIN: GB00B8HX8Z88
LEI: 2138002S5BSBIZTD5I60
South African income tax number: 9432434182
(“Mediclinic”, the “Company”, or the “Group”)
15 December 2020
NOTIFICATION OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL
RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
Awards under the Company's Long-Term Incentive Plan
As disclosed in the Directors’ Remuneration Report of 1 June 2020 for the year ending 31 March 2020
(the “FY20 DRR”), Mediclinic’s Remuneration Committee had intended to disclose prospectively the
performance metrics for awards granted during the current financial year (“FY21”) under the Company’s
Long-Term Incentive Plan (the “LTIP”). However, given the uncertainty presented by the COVID-19
pandemic (the “pandemic”) and the difficulties associated with setting meaningful targets at the time,
the Committee communicated that it had chosen to defer a decision on these metrics and levels of any
awards made under the LTIP (typically granted in June) until later during FY21. The Committee debated
these at length in recent months and, in line with the commitments made in the FY20 DDR, has
consulted with major shareholders in advance of concluding on the matter.
Taking into consideration feedback received from shareholders , the Committee has now decided to
approve the awards and corresponding metrics set out below.
Awards granted under the Company's Long-Term Incentive Plan
On 14 December 2020, awards over ordinary shares in Mediclinic (“shares”) were granted to the
following Directors and other persons discharging managerial responsibilities (“PDMRs”) under the
Company’s LTIP, approved by shareholders on 22 July 2020.
Name Director/ PDMR Number of shares awarded
under the LTIP 1
Dr Carel Aron van der Merwe Director 390 661
Petrus Jurgens Myburgh Director 216 411
David John Hadley PDMR 158 645
Gert Cornelis Hattingh PDMR 83 946
Dr René Toua PDMR 67 222
Magnus Oetiker PDMR 125 538
Koert Hendrik Stefanus Pretorius PDMR 87 651
Dr Dirk Cornelius le Roux PDMR 65 787
Dr Daniel Liedtke PDMR 156 076
Dr Tyson Bruno Welzel PDMR 53 421
Note:
1 Directors’ aw ards will be settled in shares upon vesting, and w ill be subject to a further two-year holding period. Aw ards
granted to other PDMRS w ill be settled in cash upon vesting, also based on the average of the middle-market quotations
of a share during a period of five dealing days ending w ith the dealing day before the day of vesting.
The awards made under the LTIP were granted for nil consideration and are based on the average of
the middle-market quotations of a share during a period of five dealing days ending with the dealing
day before the day of grant, which equates to £2.75 per share.
FY21 LTIP Performance Conditions
Performance condition measured Weighting Threshold Target Stretch
(25% vesting) (62.5% vesting) (100% vesting)
Adjusted EPS for FY23 (pence)1 40% 25.0p 29.0p 33.0p
TSR ranked relative to constituents of 25% 50th percentile 62.5th percentile 75th percentile
the FTSE 250 Index excluding
financial services and extraction
(measured over three financial years)
ROIC for final year (FY23) 25% 4.5% 5.0% 6.0%
Patient Experience Index 10% Based on the consolidated score of the three divisions
achievement over the performance period2.
Notes:
1 Continues to be measured on a constant currency basis.
2 Given the impact of COVID-19 on Patient Experience scores, the Committee is continuing to keep the approach to the
measurement of this element of the plan under review. Further details on the approach w ill be set out in the 2021
Directors’ Remuneration Report.
The notifications below are made in accordance with Articles 19.1 and 19.3 of the Market Abuse Regulation.
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Dr Carel Aron van der Merwe
2. Reason for the notification
a) Position / status Group Chief Executive Officer - Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the transaction Award over ordinary shares in Mediclinic International plc granted at
nil cost under the Company’s Long Term Incentive Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£nil 390 661
d) Aggregated information
Aggregated volume 390 661
Price £nil
e) Date of the transaction 14 December 2020
f) Place of the transaction Outside a trading venue
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Petrus Jurgens Myburgh
2. Reason for the notification
a) Position / status Group Chief Financial Officer - Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the transaction Award over ordinary shares in Mediclinic International plc granted at
nil cost under the Company’s Long Term Incentive Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£nil 216 411
d) Aggregated information
Aggregated volume 216 411
Price £nil
e) Date of the transaction 14 December 2020
f) Place of the transaction Outside a trading venue
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name David John Hadley
2. Reason for the notification
a) Position / status Chief Executive Officer – Mediclinic Middle East
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the transaction Award over ordinary shares in Mediclinic International plc grant ed at
nil cost under the Company’s Long Term Incentive Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£nil 158 645
d) Aggregated information
Aggregated volume 158 645
Price £nil
e) Date of the transaction 14 December 2020
f) Place of the transaction Outside a trading venue
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Gert Cornelis Hattingh
2. Reason for the notification
a) Position / status Group Chief Governance Officer - Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the transaction Award over ordinary shares in Mediclinic International plc granted at
nil cost under the Company’s Long Term Incentive Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£nil 83 946
d) Aggregated information
Aggregated volume 83 946
Price £nil
e) Date of the transaction 14 December 2020
f) Place of the transaction Outside a trading venue
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Dr René Toua
2. Reason for the notification
a) Position / status Group Chief Clinical Officer - Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions h ave been
conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the transaction Award over ordinary shares in Mediclinic International plc granted at
nil cost under the Company’s Long Term Incentive Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£nil 67 222
d) Aggregated information
Aggregated volume 67 222
Price £nil
e) Date of the transaction 14 December 2020
f) Place of the transaction Outside a trading venue
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Magnus Oetiker
2. Reason for the notification
a) Position / status Group Chief Strategy and Human Resources Officer – Mediclinic
International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the transaction Award over ordinary shares in Mediclinic International plc granted at
nil cost under the Company’s Long Term Incentive Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£nil 125 538
d) Aggregated information
Aggregated volume 125 538
Price £nil
e) Date of the transaction 14 December 2020
f) Place of the transaction Outside a trading venue
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Koert Hendrik Stefanus Pretorius
2. Reason for the notification
a) Position / status Chief Executive Officer – Mediclinic Southern Africa
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the transaction Award over ordinary shares in Mediclinic International plc granted at
nil cost under the Company’s Long Term Incentive Plan
c) Price(s) and volume(s)
Price(s) Volume(s)
£nil 87 651
d) Aggregated information
Aggregated volume 87 651
Price £nil
e) Date of the transaction 14 December 2020
f) Place of the transaction Outside a trading venue
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Dr Dirk Cornelius le Roux
2. Reason for the notification
a) Position / status Group Chief Information Officer - Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the transaction Award over ordinary shares in Mediclinic International plc granted at
nil cost under the Company’s Long Term Incentive Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£nil 65 787
d) Aggregated information
Aggregated volume 65 787
Price £nil
e) Date of the transaction 14 December 2020
f) Place of the transaction Outside a trading venue
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Dr Daniel Liedtke
2. Reason for the notification
a) Position / status Chief Executive Officer: Hirslanden
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the transaction Award over ordinary shares in Mediclinic International plc granted at
nil cost under the Company’s Long Term Incentive Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£nil 156 076
d) Aggregated information
Aggregated volume 156 076
Price £nil
e) Date of the transaction 14 December 2020
f) Place of the transaction Outside a trading venue
1. Details of PDMR / person closely associated with them (“PCA”)
a) Name Dr Tyson Bruno Welzel
2. Reason for the notification
a) Position / status Group Chief Innovation Officer –Mediclinic International plc
b) Initial notification / Initial Notification
amendment
3. Details of the issuer, emission allowance market participant, auction platform, auctioneer
or auction monitor
a) Name Mediclinic International plc
b) LEI 2138002S5BSBIZTD5I60
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii)
each type of transaction; (iii) each date; and (iv) each place where transactions have been
conducted
a) Description of the Ordinary Shares
financial instrument
Identification Code GB00B8HX8Z88
b) Nature of the transaction Award over ordinary shares in Mediclinic International plc granted at
nil cost under the Company’s Long Term Incentive Plan
c) Price(s) and volume(s) Price(s) Volume(s)
£nil 53 421
d) Aggregated information
Aggregated volume 53 421
Price £nil
e) Date of the transaction 14 December 2020
f) Place of the transaction Outside a trading venue
About Mediclinic International plc
Mediclinic is a diversified international private healthcare services group, established in South Africa in
1983, with divisions in Switzerland, Southern Africa (South Africa and Namibia) and the United Arab
Emirates ("UAE").
The Group’s core purpose is to enhance the quality of life.
Its vision is to be the partner of choice that people trust for all their healthcare needs.
Mediclinic is focused on providing specialist-orientated, multi-disciplinary services across the continuum
of care in such a way that the Group will be regarded as the most respected and trusted provider of
healthcare services by patients, medical practitioners, funders and regulators of healthcare in each of
its markets.
At 30 September 2020, Mediclinic comprised 76 hospitals, eight sub-acute and specialised hospitals,
17 day case clinics and 18 outpatient clinics. Hirslanden operat ed 17 hospitals and four day case clinics
in Switzerland with more than 1 900 inpatient beds; Mediclinic Southern Africa operations included 52
hospitals (three of which in Namibia), eight sub-acute and specialised hospitals and 11 day case clinics
(four of which operated by Intercare) across South Africa, and more than 8 700 inpatient beds; and
Mediclinic Middle East operated seven hospitals, two day case clinics and 18 outpatient clinics with
more than 900 inpatient beds in the UAE. In addition, under management contracts, Mediclinic Middle
East operates one hospital in Abu Dhabi and will open a 200-bed hospital in the Kingdom of Saudi
Arabia in mid-2022.
The Company’s primary listing is on the London Stock Exchange (“LSE”) in the United Kingdom, with
secondary listings on the JSE in South Africa and the Namibian Stock Exchange in Namibia.
Mediclinic also holds a 29.9% interest in Spire Healthcare Group plc, a leading private healthcare group
based in the United Kingdom and listed on the LSE.
For further information, please contact:
Company Secretary, Link Company Matters Limited
Jayne Meacham / Caroline Emmet
+44 (0)20 7954 9569
Investor Relations, Mediclinic International plc
James Arnold, Head of Investor Relations
ir@mediclinic.com
+44 (0)20 3786 8181
Media queries
FTI Consulting
Ben Atwell/Ciara Martin – UK
+44 (0)20 3727 1000
Sherryn Schooling – South Africa
+27 (0)21 487 9000
Registered address: 6th Floor, 65 Gresham Street, London, EC2V 7NQ, United Kingdom
Website: www.mediclinic.com
Corporate broker (United Kingdom): Morgan Stanley & Co International plc and UBS Investment Bank
JSE sponsor (South Africa): Rand Merchant Bank (A division of FirstRand Bank Limited)
NSX sponsor (Namibia): Simonis Storm Securities (Pty) Ltd
Date: 15-12-2020 12:30:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.
Sharenet Sites 
